Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorToren, Paulen
dc.contributor.authorWong, Lih-Mingen
dc.contributor.authorTimilshina, Narharien
dc.contributor.authorAlibhai, Shabbiren
dc.contributor.authorTrachtenberg, Johnen
dc.contributor.authorFleshner, Neilen
dc.contributor.authorFinelli, Antonioen
dc.identifier.citationCanadian Urological Association Journal = Journal De L'association Des Urologues Du Canada; 8(9-10): E702-7en
dc.description.abstractThe use of prostate-specific antigen (PSA) in active surveillance (AS) for prostate cancer is controversial. Some consider it an unreliable marker and others as sufficient evidence to exclude patients from AS. We analyzed our cohort of AS patients with a PSA over 10 ng/mL.We included patients who had clinical T1c-T2a Gleason ≤6 disease, and ≤3 positive cores with ≤50% core involvement at diagnostic biopsy and ≥2 total biopsies. Patients were divided into 3 groups: (1) those with baseline PSA >10 ng/mL, (2) those with a PSA rise >10 ng/mL during follow-up; and (3) those with a PSA <10 ng/mL throughout AS. Adverse histology was defined as biopsy parameters exceeding the entry criteria limits. We further compared this cohort to a concurrent institutional cohort with equal biopsy parameters treated with immediate radical prostatectomy.Our cohort included 698 patients with a median follow-up of 46.2 months. In total, 82 patients had a baseline PSA >10 ng/mL and 157 had a PSA rise >10 ng/mL during surveillance. No difference in adverse histology incidence was detected between groups (p = 0.3). Patients with a PSA greater than 10 were older and had higher prostate volumes. Hazard ratios for groups with a PSA >10 were protective against adverse histology. Larger prostate volume and minimal core involvement appear as factors related to this successful selection of patients to be treated with AS.These results suggest that a strict cut-off PSA value for all AS patients is unwarranted and may result in overtreatment. Though lacking long-term data and validation, AS appears safe in select patients with a PSA >10 ng/mL and low volume Gleason 6 disease.en
dc.titleActive surveillance in patients with a PSA >10 ng/mL.en
dc.typeJournal Articleen
dc.identifier.journaltitleCanadian Urological Association journal = Journal de l'Association des urologues du Canadaen
dc.identifier.affiliationDepartment of Urology, St. Vincent's Hospital and Austin Health, University of Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Urologic Sciences, University of British Columbia, Vancouver, BC;en
dc.identifier.affiliationDepartment of Medicine and Institute of Health Policy, Management, and Evaluation, University Health Network and University of Toronto, Toronto, ON.en
dc.identifier.affiliationDepartment of Surgery (Urology), University of Toronto, Princess Margaret Hospital, Toronto, ON;en
dc.type.austinJournal Articleen
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jul 2, 2021

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.